How it is diagnosed?

  • Ph-like-ALL is diagnosed by Fluorescence in situ hybridization (FISH) using FISH probes like ABL1, ABL2, CRLF2, EPOR1, CSF1R, JAK2, PDGFRB, PDGFRA, testing for these may aid in risk stratification
  • It is important to check for these markers to decide whether adding tyrosine kinase inhibitors (TKIs) to current therapy will improve the survival of patients with this type of leukemia.
  • ABL – class fusions include ABL1, ABL2, PDGFRB, and CSF1R rearrangements can be sensitive towards ABL inhibitors such as Imatinib or Dasatinib.
  • In Ph-like-ALL cases harboring CRLF2 & JAK2 alterations, the utility of Janus Kinase inhibitor is being explored. NCCN recommends that pediatric and AYA patients with Ph-like-ALL with early or late first relapse, the panel recommends initial treatment with systemic therapy